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C A N C E R
Targeting the scaffolding role of LSD1 (KDM1A)  
poises acute myeloid leukemia cells for retinoic  
acid–induced differentiation
Roberto Ravasio1, Elena Ceccacci1*, Luciano Nicosia1*, Amir Hosseini1, Pier Luigi Rossi1, 
Iros Barozzi2, Lorenzo Fornasari1,3, Roberto Dal Zuffo4, Sergio Valente5, Rossella Fioravanti5, 
Ciro Mercurio4, Mario Varasi4, Andrea Mattevi6, Antonello Mai5, Giulio Pavesi7,  
Tiziana Bonaldi1, Saverio Minucci1,7,8†
The histone demethylase LSD1 is deregulated in several tumors, including leukemias, providing the rationale for 
the clinical use of LSD1 inhibitors. In acute promyelocytic leukemia (APL), pharmacological doses of retinoic acid 
(RA) induce differentiation of APL cells, triggering degradation of the PML-RAR oncogene. APL cells are resistant 
to LSD1 inhibition or knockout, but targeting LSD1 sensitizes them to physiological doses of RA without altering 
of PML-RAR levels, and extends survival of leukemic mice upon RA treatment. The combination of RA with LSD1 
inhibition (or knockout) is also effective in other non-APL, acute myeloid leukemia (AML) cells. Nonenzymatic 
activities of LSD1 are essential to block differentiation, while RA with targeting of LSD1 releases a differentiation 
gene expression program, not strictly dependent on changes in histone H3K4 methylation. Integration of 
proteomic/epigenomic/mutational studies showed that LSD1 inhibitors alter the recruitment of LSD1-containing 
complexes to chromatin, inhibiting the interaction between LSD1 and the transcription factor GFI1.
INTRODUCTION
Histone methylation is dynamically controlled by histone methyl-
transferases and histone demethylases (KDMs). Among KDMs, 
lysine-specific demethylase 1 (LSD1; KDM1A) works mainly as a 
transcriptional co-repressor, which catalyzes the demethylation of 
mono- and dimethylated histone H3 lysine 4 (1, 2). LSD1 is essential for 
embryonic development (3) and is required for many physiological pro-
cesses (4, 5). During hematopoietic differentiation, GFI1 (growth fac-
tor independent 1)/GFI1b transcription factors recruit LSD1 to their 
target genes and maintain lineage-specific gene expression (6–9).
Aberrant histone methylation has been described in cancer (10). 
LSD1 has been found overexpressed in several tumors and has been 
shown to be required for maintenance of acute myeloid leukemia 
(AML) cells (11, 12). Several inhibitors of LSD1, targeting its cata-
lytical activity, have been developed, most of which derive from the 
monoamine oxidase inhibitor tranylcypromine (10). Treatment of 
AML cells with LSD1 inhibitors (LSD1i) showed a highly variable 
pattern of response (13). Sensitivity of AML cells to LSD1 inhibi-
tion can be restored by combination with other drugs, such as reti-
noic acid (RA) (11, 13). LSD1i as single agents or in combination 
with RA have therefore entered phase 1/2A clinical trials in patients 
with AML. The molecular mechanisms underlying response of AML 
cells to LSD1i remain, however, largely unknown. APL (acute pro-
myelocytic leukemia) is an AML subtype caused by the promyelo-
cytic leukemia (PML)–RA receptor (RAR) fusion oncoprotein. 
PML-RAR works as an altered transcription factor and modifies the 
epigenetic landscape of APL cells, causing differentiation block at 
the promyelocytic stage (14). Pharmacological doses of RA lead to 
degradation of the fusion protein, terminal differentiation of leukemic 
cells, and, in combination with other agents (chemotherapy or arsenic), 
definitive cure for most patients with APL, making this form of cancer 
an attractive model system for the study of tumor cell response to 
therapy (15, 16).
We showed that APL cells are resistant to pharmacological in-
hibition of LSD1 and that LSD1 inhibition sensitizes APL cells to 
physiological concentrations of RA (17). Here, we have investigated 
the molecular mechanisms underlying the sensitization to RA by 
LSD1 inhibition in AML cells (APL and non-APL), which are in-
trinsically resistant to LSD1 inhibition.
RESULTS
LSD1 inhibition sensitizes AML cells to physiological 
concentrations of RA
We tested the effect of the LSD1i MC_2580 (18, 19), alone or in combina-
tion with RA, on a panel of 21 AML cell lines representative of all 
AML subtypes. LSD1i alone considerably affected the growth (>70% 
inhibition) of a small subset of cell lines (Kasumi-1, SKNO-1, and 
EOL-1 cells). Similarly, low doses of RA (0.01 to 0.1 M) had a minor 
effect on the great majority of the cell lines, and only a few of them 
responded markedly to treatment (EOL-1, MonoMac1, and MV4-
11 cells). The combination of RA with MC_2580 had a remarkable 
impact on the viability of almost all cell lines, both resistant and sensi-
tive to LSD1 inhibition alone (Fig. 1A).
Confirming previous findings, APL cells (NB4) were not sensitive 
to LSD1 inhibition or to physiological doses of RA (0.01 M, RA 
low), while pharmacological doses of RA (1 M, RA high) markedly 
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Fig. 1. LSD1 inhibition sensitizes AML cells to physiological concentrations of RA. (A) Heat map representing the results of cell proliferation assays performed on 
21 AML cell lines treated with MC_2580 (2 M) and/or RA as indicated. Values are normalized on dimethyl sulfoxide (DMSO) treatment. The AML French-American-British 
classifications of each cell line are in parentheses. (B) Growth curves of NB4 APL cells treated as indicated. (C) Morphological analysis by May-Grünwald-Giemsa staining 
of NB4 cells treated for 96 hours in liquid culture as indicated. (D) Colony-forming ability, scored after 7 days, of 1000 NB4 cells plated in methylcellulose medium and 
treated with MC_2580 (2 M) and/or 0.01 M RA and 1 M RA. Means and SDs of three independent experiments are shown. C.F.U., colony-forming units. (E) Analysis of 
CD11b mRNA levels in NB4 cells treated for 96 hours in liquid culture as indicated. Values are normalized against GAPDH (glyceraldehyde phosphate dehydrogenase) 
and referred to DMSO. The graph represents the mean and SD of three independent experiments. FC, fold change. (F) Western blot showing depletion of LSD1 in NB4 
cells knocked out for LSD1 (LSD1 KO). WT, wild type. (G) Proliferation assays of NB4 and NB4 LSD1 KO cells after 24, 48, and 72 hours of the indicated treatments (DMSO 
as control). (H) Expression of CD11b by fluorescence-activated cell sorting (FACS) in NB4 and NB4 LSD1 KO cells after 24, 48, and 72 hours of the indicated treatments 
(DMSO as control). (I) Kaplan-Meier survival plots for mice transplanted with murine APL cells and treated as indicated (n = 6 for each treatment group). Pink shaded area 
indicates the duration of RA treatment (21 days, pellet), while LSD1i (DDP_38003) was administrated twice a week orally (OS) for the entire duration of RA treatment (total, 
six times). P values were obtained using analysis of variance (ANOVA).
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reduced cell proliferation. The combination of LSD1i with RA low 
reduced cell proliferation in liquid culture and colony-forming ability 
in semisolid culture (Fig. 1, B and C). The observed phenotype was 
due to cell differentiation, as assessed by the induction of the 
myeloid differentiation marker CD11b and morphological changes 
associated with neutrophilic differentiation (Fig. 1, D and E).
To assess whether the effect of LSD1i was specific, we depleted 
LSD1 by CRISPR-Cas9 or by a retroviral mediated knockdown 
(Fig. 1F and fig. S1). LSD1 depletion did not affect viability of NB4 
cells (fig. S1), but it enhanced their sensitivity to RA low, as evidenced 
by the reduction of cell proliferation and the induction of CD11b 
(Fig. 1, G and H). LSD1 depletion thus mimics the effects of LSD1 
inhibition, confirming the specificity of the LSD1i.
We then measured the effect of LSD1 depletion/inhibition on 
global levels of histone H3K4 methylation by quantitative mass 
spectrometry (MS) (fig. S2). We observed, in all cases, an increase in 
global H3K4me2 and H3K4me3 levels, with the H3K4me3 slight 
increase likely being a consequence of H3K4me2 accumulation.
Last, we tested the effect of LSD1i and RA combination in vivo. 
We tested DDP_38003 as LSD1i (20) since MC_2580 cannot be used 
in vivo. As previously described, all control mice (either treated with 
placebo or vehicle) died within 3 weeks (median survival, 21 days), 
and RA treatment induced differentiation and significantly prolonged 
survival (median survival, 49 days; Fig. 1I). Treatment with the 
LSD1i alone prolonged survival to a lesser extent than RA (median 
survival, 37 days), while the combination of RA with LSD1i strongly 
potentiated the therapeutic effect of RA, confirming the results 
obtained in vitro (P = 0.001 over RA treatment and P = 0.0009 over 
placebo; median survival, 70 days; fig. S3).
LSD1 inhibition allows APL cell differentiation bypassing 
the oncogenic function of PML-RAR
While pharmacological doses of RA (RA high) trigger PML-RAR 
degradation, physiological doses of RA (RA low) do not (15, 21). 
PML-RAR protein remained stable upon LSD1 inhibition, whether 
in the presence or in the absence of RA low (fig. S4A). PML-RAR 
alters the normal assembly of PML nuclear bodies, inducing a micro- 
speckled pattern of PML (22). RA high induced degradation of 
PML-RAR and restoration of the normal pattern of PML nuclear 
bodies (fig. S4B). Consistent with the results in fig. S4A, MC_2580 
did not alter the micro-speckled pattern of PML both in the pres-
ence and in the absence of RA low. We then investigated PML-RAR 
binding to its target genes after the different treatments (fig. S4C). 
We performed chromatin immunoprecipitation (IP)–quantitative 
polymerase chain reaction (ChIP-qPCR) on PML-RAR-Regulated 
Adapter Molecule 1 (PRAM1) and Phosphoinositide 3-kinase 
delta (PI3KD), two established PML-RAR targets in NB4 cells (23), 
and observed that LSD1 inhibition and RA low did not alter PML-RAR 
recruitment on those genes, while RA high displaced PML-RAR 
from chromatin and/or triggered degradation of the fusion protein.
Comparing their genomic distribution in NB4 cells, we observed 
that PML-RAR shares most of its binding sites with LSD1 (fig. S4D).
We then measured PML-RAR and LSD1 occupancy on genes 
activated only by the cotreatment and genes activated by RA high: 
Genes specifically regulated by the cotreatment show a significantly 
lower PML-RAR occupancy (P < 0.01) compared to genes activated 
by high concentrations of RA (Fig. 2F).
Last, we checked whether PML-RAR is able to recruit LSD1 on 
specific genomic targets using the U937-derived PR9 cell line, which 
express PML-RAR under a zinc-inducible promoter (23). LSD1 
peaks (97%) in PR9 cells remain stable after PML-RAR induction, 
showing that LSD1 is not recruited by PML-RAR (fig. S4E).
Together, these results indicate that the combined treatment with 
LSD1i and RA low allows differentiation and growth arrest of APL with-
out affecting PML-RAR stability and its recruitment on chromatin.
LSD1 regulates differentiation of APL cells
We performed washout experiments to define whether there is a 
temporal window of LSD1 inhibition sufficient to commit NB4 cells 
to differentiation in the presence of physiological concentrations of 
RA. We found that treatment of at least 24 hours in the presence of 
RA low led to a response comparable to continuous cotreatment 
(fig. S5). We thus determined the gene expression profile of NB4 
cells after 24 hours of treatment with MC_2580 and/or RA by RNA 
sequencing (RNA-seq). LSD1 inhibition [and LSD1 knockout (KO)] 
had only a modest effect on gene transcription, both in terms of the 
number of modulated genes and in the magnitude of their regulation 
(Fig. 2A and fig. S5). Only a few genes were down-regulated upon 
LSD1 inhibition (Fig. 2A).
LSD1 inhibition, however, markedly potentiated the effect of 
physiological concentrations of RA, doubling the number of regulated 
genes compared to treatment with RA low alone. Although the 
combination of MC_2580 with RA low regulated almost all of the 
genes regulated by RA high, it specifically induced a subset of 382 
additional genes (Fig. 2B). The large majority of regulated genes falls 
within gene categories associated with hematopoietic development 
and differentiation (fig. S5D). These observations suggest that while the 
combinatorial treatment and RA high induced a similar differentiation 
program, the combination had a larger impact on transcription than 
RA high: The combination had a stronger effect on cell proliferation 
than that observed with RA high alone (Fig. 1B).
H3K4me2 accumulation in regulatory regions after 
treatment does not correlate with induction of transcription
We assessed the genome-wide distribution of LSD1 in NB4 cells by 
ChIP sequencing (ChIP-seq). LSD1 binds preferentially regulatory 
regions (fig. S6) of genes related to hematopoiesis and cell differentia-
tion (Fig. 2C). We next performed ChIP-seq for H3K4me1/me2/me3 
and H3K27 acetylation upon the different drug treatments and 
observed a marked reorganization of the chromatin. In particular, 
there was an evident rearrangement of active super-enhancers after 
the combination of LSD1 inhibition and RA low, with 207 newly 
activated super-enhancers, of which 118 of 207 were uniquely activated 
in the cotreatment and not by high doses of RA (Fig. 2D). Consistent 
with the global increase observed by mass spectrometry, we observed 
a local increase of H3K4me2 at LSD1-bound regulatory regions after 
LSD1i. We separately analyzed chromatin changes subsequent to 
the different treatments occurring in the subset of genes specifically 
induced by the cotreatment (n = 382) and those similarly induced 
by both RA high and cotreatment (n = 486). Active transcription is 
positively correlated with the presence of both H3K4me3 and H3K27ac 
(fig. S6). LSD1 inhibition, alone or in combination with RA low, 
induced an increase in the levels of H3K4me2. This chromatin change 
is not directly associated with active transcription, as an increase in 
its levels is also present after treatment with high doses of RA at the 
promoters and enhancers of those genes that are not induced by RA 
high (Fig. 2E). Thus, an increase in H3K4me2 levels is not sufficient 
to trigger gene expression changes.
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LSD1 catalytic activity is dispensable for sensitization 
to RA-induced differentiation
We then reconstituted LSD1 KO NB4 cells with either wild-type or 
a catalytically inactive LSD1 mutant (K661A-LSD1) (Fig. 3A). While 
LSD1 KO cells were hypersensitive to low doses of RA, LSD1 and 
K661A-LSD1 reconstituted cells were insensitive to RA low, recapitulat-
ing the phenotype of NB4 wild-type cells (Fig. 3B). Consistently, after 
treatment with RA low of both LSD1 and K661A-LSD1 reconstituted 
Fig. 2. LSD1 plays a key role in the control of differentiation of APL cells. (A) RNA sequencing (RNA-seq) was performed in NB4 cells treated with MC_2580 and/or RA 
(0.01 and 1 M) for 24 hours and DMSO as control. Left: The bar plot represents number of genes regulated [up- or down-regulated with respect to control; RPKM (reads 
per kilobase million) > 0.5; log2(FC) > 1.5] upon the indicated treatments. Right: The box plot shows magnitude of induction by the indicated treatment versus control 
(DMSO). (B) Venn diagrams indicating the sum of all regulated genes, number of genes regulated by each individual treatment, and number of genes regulated by both 
treatments in NB4 cells treated with MC_2580 and 0.01 M RA versus 1 M RA. (C) Gene Ontology (biological processes) analysis of LSD1 target genes in NB4 cells. Adjusted 
P values and relative enrichment (color coded) are shown for each class. (D) Scatter plots of super-enhancers in cells treated with MC_2580 + 0.01 M RA. All stitched 
regions were ranked by H3K27ac signal. Super-enhancers and typical enhancers were in different colors as indicated. (E) Box plot analysis of H3K4me2 enrichment upon 
indicated treatment at enhancers (left) and promoters (right) of the 382 genes shown in Fig. 3B. Values are represented as log10FC versus DMSO.
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cells, we did not observe an increase in CD11b-expressing cells 
(Fig. 3C). By ChIP-qPCR, we observed that wild-type LSD1, but not 
the catalytically inactive K661A-LSD1, was able to reduce the levels of 
H3K4me2 at LSD1 target regions (Fig. 3D). These data demonstrate 
that LSD1 catalytic function is dispensable for its ability to control 
differentiation of NB4 cells.
LSD1 pharmacological inhibition disrupts its interaction 
with GFI1
The above results demonstrate that nonenzymatic functions of LSD1 
are critical for its activities. We hypothesized that LSD1 may have a 
main scaffolding role, and that LSD1i could somehow interfere with 
the interaction between LSD1 and other proteins. To verify this hy-
pothesis, we used an approach of Stable Isotope Labelling by Amino-
acids in Cell culture (SILAC)–based proteomics in combination 
with LSD1 IP to study the LSD1 interactome in NB4 cells (Fig. 4A). 
By using three different biological replicates, we defined 147 LSD1 
putative interactors (Fig. 4, B and C). Among them, we enriched the 
CoREST complex, as expected [histone deacetylase 1 (HDAC1), 
HDAC2, REST corepressor 1 (RCOR1), and RCOR3]. Western blot 
analysis of different LSD1 interactors validated the mass spectrometry 
data (Fig. 4D).
We then profiled the changes in the LSD1 interactome following 
treatment with MC_2580 (Fig. 4E). Most of the interactors remained 
Fig. 3. The catalytic activity of LSD1 is dispensable. (A) Western blot analysis of LSD1 levels in NB4 LSD1 KO cells transduced with expression vectors encoding for 
wild-type LSD1 or the catalytically inactive mutant K661A-LSD1. Empty vector was used as control, and actin served as loading control. (B) Growth curves of NB4 LSD1 
KO cells transduced with empty vector, LSD1, or K661A-LSD1 and treated with 0.01 M RA (DMSO as control treatment). (C) Percentage of CD11b-expressing cells 
assessed by FACS in NB4 LSD1 KO cells transduced with expression vectors encoding for LSD1, K661A-LSD1, or empty vector, treated with 0.01 M RA (or DMSO as control) 
for 24 hours. (D) H3K4me2 enrichment at the promoter of PI16 (left), ITGAM (center), and TGM2 (right) in NB4 and NB4 LSD1 KO cells transduced with expression vectors 
encoding for LSD1, K661A-LSD1, or empty vector, assessed by ChIP-qPCR. The results represent percentage of input chromatin. Error bars indicate SD from triplicate 
experiments, and P values were determined by a two-tailed unpaired Student’s t test (*P < 0.05, **P < 0.01, and ***P < 0.001).
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stably associated with LSD1 upon drug treatment. The binding of 
the known interactor GFI1 to LSD1, however, was strongly affected 
by the inhibitor (Fig. 4F). IP of endogenous GFI1 with anti-LSD1 
antibodies in untreated and treated cells (using two different LSD1i, 
MC_2580 and DDP_38003) confirmed the results (Fig. 4G). Recipro-
cal IP using anti-GFI1 antibodies in untreated and treated NB4 cells 
with the drugs MC_2580 and DDP_38003 validated the previous 
results (fig. S7A). The catalytic inactive LSD1 mutant (K661A-
LSD1) bound to GFI1 in a comparable manner to wild-type LSD1, 
and the LSD1i reduced the LSD1 mutant/GFI1 interaction (Fig. 4H 
and fig. S7) as well. These data show that the LSD1i that we used 
hamper the interaction between LSD1 and GFI1, implying that 
LSD1i target catalytic and noncatalytic functions of LSD1.
Sensitization of LSD1 inhibition to RA treatment depends 
on the interaction LSD1-GFI1 in APL and non-APL AML cells
We then analyzed the genome-wide distribution of binding sites for 
GFI1 and LSD1 by ChIP-seq, which resulted to be largely overlapping 
(Fig. 5A). Upon treatment with MC_2580, LSD1 was evicted from 
732 GFI1-bound regions (Fig. 5B). We analyzed three GFI1 target 
genes and found that HDAC1 was also displaced (Fig. 5C). GFI1 
recruitment to chromatin, in contrast, appears to be less affected 
(fig. S8).
To validate our hypothesis that the disruption of LSD1-GFI1 
interaction is the causative event for the sensitization to RA by LSD1i, 
we took advantage of an LSD1 mutant (D553,555,556A) that is not 
able to bind the SNAIL/GFI1 (SNAG) domain of GFI1, which is re-
quired for their interaction (Fig. 5D) (24). Forced expression of 
D553,555,556A-LSD1 did not rescue NB4 KO cells from their sensi-
tivity to low doses of RA (Fig. 5E), failing to establish a differentia-
tion block and confirming the validity of our hypothesis.
Last, we decided to check whether these findings are restricted to 
APL or can be observed also in other AML subtypes. We therefore 
knocked out LSD1 in MOLM13 cells, an acute monocytic leukemia 
AML cell line resistant to LSD1 inhibition (Fig. 6A). LSD1 depletion 
did not impair the viability of MOLM13 cells but strongly potentiated 
the differentiation induced by RA treatment (Fig. 6, B and C). RA 
treatment of LSD1 KO cells reconstituted with either wild-type LSD1 
or the catalytic mutant K661A showed restoration of the phenotype 
observed for wild-type MOLM13 cells, while reconstitution with 
the LSD1-D553,555,556A mutant continued to show an enhanced 
sensitivity to RA (Fig. 6, D to F).
Together, these data demonstrate that LSD1-GFI1 interaction 
is fundamental for the establishment of a differentiation block by 
LSD1 in AML cells, and that the sensitization to RA triggered by 
LSD1i relies on the disruption of LSD1-GFI1 interaction.
DISCUSSION
LSD1 has emerged as an interesting target for cancer therapy, and 
LSD1i have entered clinical trials for treatment of several cancer 
types, including AML. Only a minority of AML cells are sensitive to 
LSD1 inhibition as single treatment (25); a strong cooperative ac-
tion of LSD1i and RA can be, however, measured even in those 
AML subtypes not responsive to either drug alone (11), justify-
ing a clinical investigation of this approach (ClinicalTrials.gov: 
NCT02261779, NCT02273102, and NCT02717884). An analysis of 
the mechanism of action of LSD1i in combination with RA has not 
been reported so far: Focusing on this phenomenon in cells resis-
tant to LSD1i provides useful insights to optimize the use of LSD1i 
in a clinical setting.
Here, we show that the combination of RA and LSD1i, or LSD1 
genetic KO, leads to complete differentiation of AML cells resistant 
to LSD1i alone. LSD1 inhibition has almost no impact on global 
gene expression, but the combination of RA and LSD1i leads to the 
induction of a large set of genes involved in cellular differentiation 
and to profound changes in chromatin structure, including activation 
and decommissioning of super-enhancers. Since these changes occur 
in the continuous presence of PML-RAR, they must bypass the action 
of the oncogene, and in fact, we show that this mechanistic model 
applies also to other AML subtypes, not expressing PML-RAR.
The correlation between transcriptional derepression and LSD1 
catalytic activity is an open debate. LSD1 demethylase activity seems to 
be essential to maintain the undifferentiated state of human embryonic 
stem cells (26) and to override oncogene-induced senescence (27). 
In contrast, the catalytic activity of LSD1 is not required to block 
differentiation of AML cells sensitive to LSD1 inhibition (28).
Here, we analyze the role of LSD1 catalytic activity in AML cells 
resistant to LSD1 inhibition. We show that reconstitution of LSD1 
KO cells with either the wild-type or a catalytically inactive form of 
the enzyme recovers the differentiation block of leukemic cells, al-
though the inactive LSD1 (unlike the wild-type form) fails to modi-
fy chromatin at its targets. We therefore conclude that the catalytic 
activity of LSD1 is not involved in the establishment of a differenti-
ation block in AML cells resistant to LSD1 inhibition.
We used a proteomic approach to analyze the LSD1 interactome 
in the absence and in the presence of LSD1 inhibition. We show 
that while most interactors remain associated with LSD1 upon 
treatment with MC_2580, the inhibitor leads to the selective dis-
sociation of GFI1 from LSD1. On the basis of these results, we 
hypothesize that the LSD1 complex is therefore not affected by 
LSD1 inhibition and that the inhibitor acts on the LSD1-GFI1 direct 
interaction. In particular, LSD1 interacts with GFI1 through the 
SNAG domain present at the N terminus of GFI1, which works as a 
molecular hook to recruit LSD1 (24). Consistently, upon inhibition, 
LSD1 (and LSD1-associated proteins, such as HDAC1) is evicted from 
chromatin at GFI1 target genes. The interaction of GFI1 with LSD1 is 
critical for the differentiation block maintained by LSD1 in the absence 
of RA. Similarly, the association of LSD1 with GFI1 has been reported 
to be also critical for maintaining the differentiation block of AML 
cells (28, 29) and medulloblastoma cells (30) sensitive to LSD1i.
The small-molecule LSD1i used in this study (MC_2580 and 
DDP_38003) are thus still able to dissociate GFI1 from a catalytically 
inactive LSD1. This feature can be explained from the three- 
dimensional structure of the enzyme-inhibitor and enzyme-GFI1 
complexes: The inhibitor and the transcription factor binding sites 
fully overlap. The inhibitor can therefore be expected to create steric 
hindrance that prevents GFI1 binding (31).
Together, our results point to a model where in AML cells resistant 
to LSD1 inhibition, LSD1 acts primarily as a scaffolding module to 
recruit the CoREST complex to transcription factors such as GFI1, 
which functions as a brake to differentiation stimuli (such as RA). The 
inhibitors of LSD1 that we used are able to trigger dissociation of the 
complex from GFI1 and favor differentiation by RA. Although further 
in vivo studies are needed to fully understand the implications of our 
observations, these results are of both mechanistical and translational 
relevance and, since most tumor cells tolerate LSD1 inhibition (25), 
further support the use of LSD1i in combination therapy.
Ravasio et al., Sci. Adv. 2020; 6 : eaax2746     8 April 2020
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
7 of 13
Fig. 4. Pharmacological inhibition of LSD1 disrupts its interaction with GFI1. (A) Schematic representation of SILAC mass spectrometry approach to identify LSD1 
interactors in NB4 cells. LC-MS/MS, liquid chromatography–tandem mass spectrometry. (B) Scatterplot showing log2 (heavy/light) ratio of forward reaction on the x axis 
(Rep1) and the log2 (light/heavy) ratio of reverse reaction on the y axis (Rep3). In the top right quadrant are represented LSD1 interactors. The blue dashed lines define the 
threshold used to define the LSD1 interactors from the background. Proteins belonging to the CoREST complex are shown in red dots. (C) Venn diagrams with numbers 
of individual and overlapping putative LSD1 interactors identified in the three different SILAC replicates. (D) Western blot analysis of LSD1 and some identified interactors 
in LSD1 IPs, with or without blocking peptide. Lamin B1 is used as loading control. (E) Schematic representation of SILAC mass spectrometry approach to identify recruited 
and evicted interactors of LSD1, upon LSD1 pharmacological inhibition with 2 M MC_2580 for 24 hours. (F) Scatterplot showing log2 (heavy/light) ratio of forward 
reaction on the x axis and the log2 (light/heavy) ratio of reverse reaction on the y axis. Proteins recruited by LSD1 after inhibition are present in the top right quadrant, 
while proteins evicted from the interaction with LSD1 after drug treatment are found in the bottom left quadrant. Proteins previously identified as interactors of LSD1 in 
NB4 are shown as red dots. The blue dashed lines define the threshold used to determine recruited and evicted proteins. (G) Western blot analysis of LSD1 and GFI1 in 
LSD1 IPs in NB4 cells treated for 24 hours with DMSO, 2 M MC_2580, or 2 M DDP_38003. (H) Western blot analysis of LSD1 and GFI1 in GFI1 IPs in NB4 LSD1 KO cells 
transduced with empty vector, wild-type, or catalytic inactive K661A-LSD1, treated with 2 M MC_2580 or DMSO.
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MATERIALS AND METHODS
Compounds
RA was purchased from Sigma-Aldrich S.r.l. (R2625). MC_2580 and 
DDP_38003 have been synthesized as previously described (17, 20).
Cell culture
All cell lines were grown according to American Type Culture Col-
lection recommendations. Cultures were maintained in a humidi-
fied tissue culture incubator at 37°C in 5% CO2.
SILAC labeling of NB4 cells
For standard SILAC labeling, NB4 cells were grown in “light” and 
“heavy” SILAC RPMI 1640 (Thermo Fisher Scientific, 89984) 
supplemented with either l-arginine and l-lysine or their heavy iso-
tope counterparts l-arginine-13C6, 15N4 hydrochloride (Arg10; 
Sigma-Aldrich, 608033) and l-lysine-13C6, 15N2 hydrochloride (Lys8; 
Sigma-Aldrich, 608041) (32). All media were supplemented with 
10% dialyzed fetal bovine serum (FBS) (26400-044, Gibco, Life 
Technologies), 1% glutamine, penicillin (100 U/ml), and strep-
tomycin (100 mg/ml).
In vivo studies
For in vivo studies, lineage-negative (lin−) cells were isolated from 
the bone marrow of 8- to 10-week-old 129SvEv mice, and murine 
PML-RAR cells were generated using a retroviral transduction and 
transplantation approach as previously described (33). The animals 
Fig. 5. The interaction of LSD1 with GFI1 is fundamental for LSD1 activity in APL cells. (A) Heat maps showing ChIP-seq signal of LSD1 and GFI1 ranked according to 
decrescent LSD1 signal. bp, base pairs. (B) Representative examples of overlapping LSD1 and GFI1 binding regions. University of California Santa Cruz Genome Browser 
profile of LSD1 and GFI1 ChIP-seq on the PI16 gene promoter and interferon regulatory factor 8 (IRF8) putative enhancer is shown. (C) HDAC1 recruitment (measured by 
ChIP-qPCR) at three genomic regions bound by both LSD1 and GFI1, before and after treatment with MC_2580. n.s., not significant. **P < 0.01 and ***P < 0.001. (D) West-
ern blot analysis of LSD1 and GFI1 in GFI IP assays performed in NB4 LSD1 KO cells reconstituted with wild-type LSD1, LSD1-D553,555,556A mutant, or empty vector (as 
control). IgG, immunoglobulin G. (E) Growth curves of NB4 LSD1 KO cells transduced with wild-type LSD1, LSD1-D553,555,556A, or empty vector and treated for the 
indicated time with 0.01 M RA (or DMSO as control).
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were checked periodically for clinical signs of disease and for pres-
ence of blast cells by May-Grünwald-Giemsa staining of blood 
smears. All-trans retinoic acid (ATRA) pellets (21-day release, 5 mg) 
or placebo pellets were implanted subcutaneously by trocar injec-
tion 10 days after cell injection. DDP_38003 was dissolved in a 
vehicle composed of 40% polyethylene glycol, molecular weight 
400 in a 5% glucose solution and orally administered at the dose of 
17 mg/kg 2 days per week, for 3 weeks. For the combination, mice 
were dosed with ATRA pellets (21-day release, 5 mg) and DDP_38003 
at the dose of 17 mg/kg following the administration schedule of the 
single treatment. In vivo studies were performed after approval 
from our fully authorized animal facility and our institutional welfare 
committee Organismo Preposto al Benessere degli Animali (OPBA) 
and notification of the experiments to the Ministry of Health (as 
required by the Italian law; Institutional Animal Care and Use 
Committee numbers: 759/2015 in accordance with European Union 
directive 2010/63).
Proliferation, cell viability, methylcellulose plating, 
and morphological characterization
For proliferation assays, cells were counted in trypan blue (Sigma- 
Aldrich, St. Louis, MO, USA). CellTiter-Glo luminescent cell viability 
assays (Promega, Madison, WI, USA) were performed following 
the manufacturer’s instructions.
Colony-forming assays were performed in methylcellulose medium 
(MethoCult H4444, Stem Cell Technology, Vancouver, BC, Canada) 
containing 10% FBS. After 7 to 10 days of culture, colonies were scored.
Cytospin preparations obtained from 200,000 cells per sample 
were stained for 8 min with May-Grünwald solution, washed 
three times in deionized water, and then incubated for 40 min with 
Fig. 6. The interaction of LSD1 with GFI1 is fundamental for LSD1 activity in non-APL AML cells. (A) Western blot analysis of LSD1 in MOLM13 wild-type and LSD1 
KO cells. Tubulin served as loading control. (B) Treatment of wild-type and LSD1 KO MOLM13 cells with 0.1 M RA (or DMSO as control). P values were obtained by unpaired 
Student’s t test (***P < 0.001). (C) Morphological analysis of MOLM13 wild-type and KO cells after 11 days of treatment with 0.1 M. (D) Western blot analysis of LSD1 in 
MOLM13 LSD1 KO cells transduced with the indicated vectors. (E) Treatment of MOLM13 LSD1 KO cells transduced with either wild-type LSD1, LSD1-K661A, and LSD1-
D553,555,556A vectors and treated with 0.1 M RA. P values were obtained by unpaired Student’s t test (**P < 0.01). (F) Morphological analysis (May-Grünwald-Giemsa 
staining) of MOLM13 LSD1 KO cells transduced with the indicated vectors and treated for 11 days with 0.1 M RA.
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Giemsa solution. After three more washes, samples were air-dried 
and evaluated.
Flow cytometry
Fluorescence-activated cell sorting (FACS) analyses were performed 
using a FACSCalibur flow cytometer (BD Biosciences, Oxford, UK). 
Cell sorting experiments were performed using a FACSAria cell 
sorter (BD Biosciences, Oxford, UK). The antibody used for flow cy-
tometry is CD11b-PE clone ICRF44 (eBioscience Inc., San Diego, CA).
Gene editing
The CRISPR-Cas9 gene editing vector lentiCRISPR v2 was a gift 
from F. Zhang (Addgene, plasmid no. 52961). The CRISPR target 
sequence CGCGGAGGCTCTTTCTTGCG in exon 1 was selected 
to knock out LSD1 and cloned into lentiCRISPR v2 vector following 
the manufacturer’s instructions.
Lentiviral vectors, retroviral vectors, and expression 
constructs
The lentiviral CRISPRv2 vector was cotransfected with vesicular 
stomatitis virus glycoprotein and dR8.2 plasmids into 293T cells, and 
the viral supernatants were produced as previously described (33). Cells 
were spin-infected with viral supernatant and selected with puromycin- 
containing medium for 3 days. After clonal growth by limiting dilu-
tion, sublines were screened by Western blotting against LSD1.
To knock down LSD1, two short hairpin RNA (shRNA) sequences 
were tested. Interfering sequences were cloned into the LMP vector 
by Xho–Eco RI double digestion. shRNA transcription in these vec-
tors is RNA polymerase II mediated and is under the control of an 
long terminal repeat promoter and expresses puromycin resis-
tance cassette (shLSD1#3, TGCTGTTGACAGTGAGCGAAGT-
GATACTGTGCTTGTCCACTAGTGAAGCCACAGATGTAGTG 
GACAAGCACAGTATCACTGTGCCTACTGCCTCGGA and 
shLSD1#5, TGCTGTTGACAGTGAGCGATCTCAGAAGATGAG-
TATTATTTAGTGAAGCCACAGATGTAAAT AATACTCATCTTCT-
GAGAGTGCCTACTGCCTCGGA).
LSD1 N-terminal truncated (172-833) wild-type and catalytic 
mutant (K661A-LSD1) constructs were a gift by E. Battaglioli (University 
of Milan). Constructs were PCR-amplified from original vectors and 
cloned into pCR 2.1-TOPO (Invitrogen) using the following primers: 
LSD1 forward, ATGTCGGGTGTGGAGGGCGCAGCTTTC and 
LSD1 reverse, TCACATGCTTGGGGACTGCTGTGC.
Products were then subcloned into the Eco RI site of the retroviral 
PINCO vector for ectopic expression. To make the D553,555,556A 
triple mutant construct described in (24), the following primers 
were used in three sequential site-directed mutagenesis reactions 
using the pCR-TOPO-LSD1WT as the template vector: LSD1_D553A 
forward, CTTAAGCACTGGGCTCAGGATGATGACTTTGAGTTC; 
LSD1_D553A reverse, GAACTCAAAGTCATCATCCTGAGCCCAGT-
GCTTAAG; LSD1_D553,555A forward, CTTAAGCACTGGGCT-
CAGGCTGATGACTTTGAGTTC; LSD1_D553,555A reverse, 
GAACTCAAAGTCATCAGCCTGAGCCCAGTGCTTAAG; 
LSD1_D553,555,556A forward, CTTAAGCACTGGGCTCAG-
GCTGCTGACTTTGAGTTC; and LSD1_D553,555,556A reverse, 
GAACTCAAAGTCAGCAGCCTGAGCCCAGTGCTTAAG.
Western blot
Antibodies used for Western blot analyses were as follows: actin (Sigma- 
Aldrich, no. A4700, clone AC-40), GFI1 (Santa Cruz Biotechnology, sc- 
376949, clone B9), GSE1 (Proteintech, no. 24947-I-AP), H3 (Abcam, 
no. 1791), H3K4me1 (Abcam, no. 8895), H3K4me2 (Abcam, no. 32356), 
H3K4me3 (Active Motif, no. 39159), HDAC1 (Abcam, no. 7028), HMG20B 
(Proteintech, no. 14582-1-AP), laminin B (Abcam, no. 16048), LSD1 
(Cell Signaling Technology, no. 2139 and Abcam, no. 17721), RAR 
(Santa Cruz Biotechnology, sc-551), tubulin (Santa Cruz Biotechnology, 
sc-32356), vinculin (Sigma-Aldrich, no. V9131, clone hVIN-1), and 
ZMYM3 (Abcam, no. 106626).
Immunofluorescence
NB4 cells, treated as indicated for 24 hours, were transferred by 
cytospin to histological glasses and fixed with 4% paraformaldehyde, 
permeabilized with 0.1% Triton X-100, and blocked with 5% normal 
goat serum. Staining was performed using a mouse anti-human PML 
antibody (PGM3) to reveal PML nuclear bodies or micro- speckles 
(34). A Cy3-conjugated goat anti-mouse (Jackson ImmunoResearch 
Laboratories Inc., West Grove, PA, USA) was used as secondary 
antibody.
ChIP and ChIP-seq analyses
Detailed protocols for ChIP are given in the Supplementary Materials. 
For histone modification, 3 × 106 cells per IP and primary antibody 
(4 g/ml) were used; for LSD1, GFI1, and PML ChIP, 40 × 106 cells 
per IP were used (10 g/ml). The obtained DNA was then quantified 
by PicoGreen and processed for ChIP-seq library preparation (as 
described for the Illumina protocol) or used for qPCR. For libraries 
preparation, 2 ng of immunoprecipitated DNA was used. Antibodies 
used for ChIP are as follows: H3K4me1 (Abcam, no. 8895), H3K4me2 
(Abcam, no. 32356), H3K4me3 (Active Motif, no. 39159), H3K27ac 
(Abcam, no. 4729), LSD1 (Abcam, no. 17721), GFI1 (Abcam, no. 
21061), PML (Santa Cruz Biotechnology, sc-5621), and immuno-
globulin G rabbit (Jackson ImmunoResearch, lot no. 134230).
Chromatin immunoprecipitation–quantitative polymerase 
chain reaction
For the validation of specific regions, ChIP-qPCRs were performed 
as follows. Immunoprecipitated DNA was diluted in 9.6 l of H2O 
per reaction, plus 400 nM primers in a final volume of 20 l in SYBR 
Green. Each ChIP experiment was performed at least three times with 
biological replicates. For ChIP-qPCRs, the following primers were 
used: negative control forward, AGCTATCTGTCGAGCAGCCAAG; 
negative control reverse, CATTCCCCTCTGTTAGTGGAAGG; 
PRAM1 forward, CCACAGAGCCTCCCCTAGA; PRAM1 reverse, 
TGCAACACCTCCCTGTGA; peptidase inhibitor 16 (PI16) forward, 
AGCCCTCACAGATGAGGAGA; PI16 reverse: GCCACACTTAC-
CATGTGCAG; Integrin subunit alpha (ITGAM) forward, GGAG-
GAGAAGTGACATGGCT; ITGAM reverse, AGGCAAAGTG-
GAGATGGTGA; transgutaminase 2 (TGM2) forward, CAGATACAG 
ACACACGCAGC; TGM2 reverse, TGGGGAGGTGTTCTTGATCC; 
CD86 forward, ACAGTCATTGCCGAGGAAGG; CD86 reverse, 
CTCATCCGTGTGTCTGTGCT; GFI1b forward, CAGGGAGGGGAA-
CAGAAGAG; and GFI1b reverse, GAACTGCAAAGCCTCTCTCG.
Active enhancers, active promoters, and super-enhancer 
identification and analysis
Active enhancers were defined as regions with overlapping peaks of 
H3K4me1 and H3K27ac that fall into distal genomic regions [defined 
as −20/−5 kb and +5/+20 kb from transcription start sites (TSS)]. 
Active promoters were defined as regions with overlapping peaks of 
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H3K4me3 and H3K27ac falling within 5 kb of RefSeq TSS. Coordinates 
of active enhancers and active promoters overlapping LSD1 peaks 
were used for histone mark analysis. Read coverage in those regions was 
computed with BEDTools suite version 2.17.0 (35) and normalized 
according to sequencing depth of each sample.
MACS peaks of H3K27ac over background were used for super- 
enhancer identification. Constituent enhancers within 12,500 base 
pairs were stitched together and ranked by input-subtracted signal 
of H3K27ac; enhancers located within a window of ±2.5 kb around TSS 
of RefSeq genes were excluded from the analysis. Super-enhancers 
were identified as those above the inflection point of the H3K27ac 
signal versus enhancer rank (36).
RNA extraction and reverse transcription qPCR
Total RNA was extracted from NB4 cells with TRIzol (Invitrogen) 
and then purified using the RNeasy kit (Qiagen). Reverse tran-
scription was performed with the SuperScript II Kit (Invitrogen), 
according to the manufacturer’s protocol. qPCRs were performed 
in triplicates in 20 l of final reaction volume containing SYBR 
Green buffer (Applied Biosystems), 20 ng of cDNA retrotrans-
cribed from the RNA, and 0.4 M of each primer mix. All the 
qPCR amplifications were performed in the AB-7000 sequence 
detection system (Applied Biosystems) at 50°C for 2 min and 95°C 
for 10 min, followed by 40 cycles at 95°C. For reverse transcription 
qPCRs, the following primers were used: glyceraldehyde phosphate 
dehydrogenase (GAPDH) forward, GCCTCAAGATCATCAG-
CAATGC; GAPDH reverse, CCACGATACCAAAGTTGTCAT-
GG; CD11b forward, AACCCCTGGTTCACCTCCT; CD11b re-
verse, CATGACATAAGGTCAAGGCTGT; GFI1b forward, 
CAGGGAGGGGAACAGAAGAG; and GFI1b reverse, GAACT-
GCAAAGCCTCTCTCG.
RNA-seq and data analysis
mRNA-seq libraries were prepared according to the TruSeq low 
sample protocol (Illumina, San Diego, CA, USA), starting with 1 g 
of total RNA per sample. Details are provided in the Supplementary 
Materials.
Protein coimmunoprecipitation analysis
NB4 nuclear fraction was quantified and diluted in IP buffer [10 mM 
tris HCl (pH 7.6), 150 mM NaCl, and 0.2% NP-40] supplemented 
with 1× Roche protease inhibitors and 0.5 mM phenylmethylsulfonyl 
fluoride (PMSF) to obtain a concentration of 2 mg/ml. Preclearing 
of the lysate was carried out by 1-hour incubation with protein G 
magnetic beads. The lysate was requantified and diluted with the IP 
buffer supplemented with protease inhibitors up to a concentration 
of 1.3 mg/ml. An aliquot of the input was collected before the addi-
tion of the desired antibody. The samples were incubated with the 
antibody overnight on a rotating wheel at 4°C. The following day, 
50 to 100 l of Dynabeads Protein G preequilibrated in phosphate- 
buffered saline (PBS) and supplemented with 0.5% bovine serum 
albumin (BSA) was added to the extracts and incubated for 3 hours 
on a rotating wheel at 4°C. Beads were then washed three times with 
IP buffer and once with washing buffer IP [10 mM tris HCl (pH 7.6), 
250 mM NaCl, and 0.2% NP-40]. Then, bound material was eluted 
by incubation with LDS Sample Buffer (NuPAGE), supplemented with 
100 mM dithiothreitol (DTT), at 95°C for 5 min. Eluted samples 
were loaded on SDS–polyacrylamide gel electrophoresis (PAGE) 
for protein separation and subsequent analysis. Antibodies used for 
protein coimmunoprecipitation are as follows: LSD1 (LSD1; Abcam, 
no. 17721) and GFI1 (sc-376949).
LSD1 coimmunoprecipitation for mass spectrometry 
analysis of protein-protein interactions
The protein content of the nuclear fraction of light and heavy samples 
was quantified by Bradford assay and diluted to a concentration of 
2 mg/ml in IP buffer [10 mM tris HCl (pH 7.6), 150 mM NaCl, and 
0.2% NP-40], supplemented with 1× protease inhibitors (Roche) 
and 0.5 mM PMSF. Preclearing of the lysates was achieved by incu-
bation with protein G magnetic beads for 1 hour on a rotating wheel 
at 4°C. The lysates were then requantified and diluted with the IP 
buffer supplemented with protease inhibitors to a concentration of 
1.3 mg/ml. A minor fraction ( 1 ⁄ 20 ) of input was collected before adding 
10 g of anti-LSD1 antibody to each sample. All samples were then 
incubated on a rotating wheel at 4°C overnight. For the acquisition 
of the basal LSD1 interactome, 120-fold molar excess of LSD1 
blocking peptide was incubated together with the antibody as negative 
control. This peptide competes with the bait and all its coassociated 
factors for the antibody binding (37). The peptide was added to the 
light channel in the forward experiment (Rep1 and Rep2) and to 
the heavy channel in the reverse experiment (Rep3). Instead, for the 
dynamic LSD1 interactome, the inhibitor MC_2580 was added to 
the heavy channel in the forward experiment and in the light one 
in the reverse replicate. The following day, 100 l of Dynabeads 
Protein G, preequilibrated in PBS supplemented with 0.5% BSA, 
was added to each sample and incubated for 3 hours on a rotating 
wheel at 4°C. Beads were then washed three times with IP buffer 
and once with the washing buffer IP [10 mM tris HCl (pH 7.6), 
250 mM NaCl, and 0.2% NP-40]. In the last washing step, light and 
heavy samples of each SILAC replicate were mixed, and the co-
immunoprecipitated proteins were eluted by incubation at 95°C 
for 5 min with the LDS Sample Buffer (NuPAGE-Invitrogen) 
supplemented with 100 mM DTT. Samples were loaded on an 
SDS-PAGE gradient gel for subsequent protein separation and 
mass spectrometry analysis.
Antibody used for the preparative LSD1 coimmunoprecipitation 
was LSD1 (Abcam, no. 17721). The blocking peptide used as mock 
control was Human KDM1/LSD1 peptide (ab17763).
In-gel digestion of immunoprecipitated proteins
In-gel digestion of gel-separated proteins was carried out with trypsin, 
as previously described (38). After digestion and extraction from the 
gel pieces, the digested peptides were desalted and concentrated by 
reversed-phase chromatography onto C18 Stage Tip microcolumns 
(39). Peptides were then eluted from the stage tips with buffer B 
(80% acetonitrile and 0.5% acetic acid), lyophilized, resuspended in 
0.1% formic acid (FA), and subjected to liquid chromatography–
tandem mass spectrometry (LC-MS/MS) analysis.
Liquid chromatography and tandem mass spectrometry
Peptide mixtures were analyzed by online nanoflow LC-MS/MS 
using an EASY-nLC 1000 (Thermo Fisher Scientific, Odense, 
Denmark) connected to a quadrupole/Orbitrap mass spectrometer 
(Q Exactive HF, Thermo Fisher Scientific) through a nanoelectro-
spray ion source. The nano-LC system was operated in one column 
setup with EASY-Spray LC Columns (length, 50 cm; inner diameter, 
75 m) packed with C18 reversed-phase resin (2 m). Solvent A 
was 0.1% FA in ddH2O, and solvent B was 80% ACN with 0.1% 
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FA. Peptides were injected at a flow rate of 500 nl/min and sepa-
rated with a gradient of 5 to 30% solvent B over 80 min, followed 
by a gradient of 30 to 60% for 10 min and 60 to 95% over 3 min at 
a flow rate of 250 nl/min. The Q-Exactive was set in the data- 
dependent mode to automatically switch between full-scan MS 
and MS/MS acquisition. MS experiments consisted of an Orbitrap 
full scan, followed by the acquisition of the 15 most intense peptide 
ions (top 15) detected in the survey MS scan. Mass spectrometer 
conditions for all experiments were as follows: full MS [Automatic 
Gain Control (AGC), 3 × 106; resolution, 60,000; mass/charge ratio 
(m/z) range, 375 to 1650; maximum ion time, 20 ms] and MS/MS 
(AGC, 15,000; maximum ion time, 80 ms; isolation width, 2 m/z 
with a dynamic exclusion time of 20 s). Singly charged ions and 
ions for which no charge state could be determined were excluded 
from the selection. Normalized collision energy was set to 28%. 
Spray voltage was set to 1.9 kV. No sheath and auxiliary gas flow. 
Heated capillary temperature was 275°C; S-lens radio frequency 
level is 50%.
LSD1 interactome data analysis
MaxQuant outputs were manually filtered for the LSD1 interac-
tome analysis according to the following parameters: Proteins 
were considered in the analysis if identified with more than two 
peptides of which at least one is unique and ratio count is greater 
than 1 (RC > 1). Peptides of the antibody used for the IP as well as 
of epidermal and hair proteins (such as keratin variants and derm-
cidin), if identified, were removed (i.e., light contaminant). To 
analyze the putative LSD1 interactors in NB4 cells, the “mixtools” 
R package was used to define two populations of specific interact-
ing and background proteins based on their SILAC ratios. Mean 
() and SD () of the interacting protein population were calculated. 
Proteins with a SILAC ratio higher than - were considered sig-
nificant. To identify the modulated proteins after LSD1 pharma-
cological inhibition, a statistical approach based on the calculation 
of the median and the SD () of the protein distribution was ap-
plied. Proteins with a SILAC ratio higher than the median +2 
were defined as recruited, while proteins with a SILAC ratio lower 
than the median –2 were defined as evicted. Once the distribu-
tions of each replicate are analyzed, the modulated proteins were 
filtered on the basis of the results of the basal LSD1 interactome, 
which sets the list of specific binders. Analysis of the protein distri-
bution of each SILAC replicate and scatter plots were obtained 
with Perseus software.
Statistical analysis
Data are presented as means ± SD. Statistical comparisons were 
carried out using two-tailed unpaired Student’s t tests, unless other-
wise specified. The number of biological (n) or technical replicates, 
the type of statistical analyses performed, and statistical significance 
are reported in the corresponding figures and figure legends.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/6/15/eaax2746/DC1
View/request a protocol for this paper from Bio-protocol.
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